May 8 (Reuters) - Pfizer Inc has agreed to settle more than 10,000 cases about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with the deal. (Reporting by Leroy Leo in Bengaluru; Editing by Devika Syamnath)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.21 USD | -2.32% | -1.00% | -1.79% |
May. 27 | US, European nations consider vaccinating workers exposed to bird flu | RE |
May. 24 | Novavax awaits FDA decision on whether its next COVID shot can be offered in US | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.82% | 164B | |
+37.94% | 727B | |
-7.89% | 354B | |
+15.42% | 328B | |
-0.44% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+4.00% | 164B | |
-1.31% | 122B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Pfizer agrees to settle more than 10,000 Zantac cancer lawsuits - Bloomberg News